Apr 1, 2009 - Teva Pharmaceutical Industries Ltd. announced today that the U.S. FDA has granted approval for the Company's Abbreviated New Drug Application to market its generic version for Bayer Healthcare Pharmaceuticals' oral contraceptive Yaz (Drospirenone and Ethinyl Estradiol) Tablets. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
The details can be read here.
No comments:
Post a Comment